Skip to content
Aussie8 – Lifestyle
Author:
广州麓鹏制药有限公司/Guangzhou Lupeng Pharmaceutical Co. LTD
Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
May 21, 2026